New monoclonal antibody for thyroid eye disease

New monoclonal antibody for thyroid eye disease
Roibeard O’hEineachain
Roibeard O’hEineachain
Published: Monday, September 28, 2020
David B Granet MD FACS FAAP FAAO
The introduction and FDA approval of the monoclonal antibody teprotumumab (Tepezza, Horizon Therapeutics) heralds a new era in the treatment of thyroid eye disease, said David B Granet, MD FACS FAAP FAAO, Shiley Eye Center, University of California, San Diego, US. “We used to say that in the future thyroid eye disease will be stopped with medication and not the scalpel. The future has arrived,” Dr Granet told the 2020 WSPOS Virtual Meeting. The human monoclonal antibody was approved for use in the United States in January 2020. It binds to the insulin-like growth factor 1 receptor (IGF-1R) and by doing so also inhibits thyroid-stimulating hormone (TSH). In this way it inhibits the inflammatory cascade thereby reducing oedema and glycosaminoglycan production. It is administered intravenously at a dosage of 20mg/kg in eight cyles over 24 weeks, Dr Granet noted. The FDA approved teprotumumab based on two randomised controlled studies showing a greater than 2.0mm reduction in proptosis in 71% and 83% of patients receiving the monoclonal antibody, compared to 20% and 10% of control patients. Dr Granet presented two case studies, one with active disease and the other with chronic disease, whose eyes in both cases returned to their normal state after completing eight cycles of treatment. “This is a game changer; however, there are side-effects and of course we have to pay attention to the teratogenicity of this in someone who might be pregnant. There may be relapses as well and it is expensive,” Dr Granet added.
Tags: thyroid eye disease
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...